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Purpose: Bacillus Calmette-Guérin (BCG)-treatment is an established treatment for bladder cancer, but
its mechanisms of action are not fully understood. High-risk non-muscle invasive bladder-cancer
(NMIBC)-patients failing to respond to BCG-treatment have worse prognosis than those undergoing
immediate radical cystectomy and identiﬁcation of patients at risk for BCG-failure is of high priority.
Several studies indicate a role for nitric oxide (NO) in the cytotoxic effect that BCG exerts on bladder
cancer cells. In this study we investigated whether NO-synthase (NOS)-gene polymorphisms, NOS2-
promoter microsatellite (CCTTT)n, and the NOS3-polymorphisms-786T4C (rs2070744) and Glu298Asp
(rs1799983), can serve as possible molecular markers for outcome after BCG-treatment for NMIBC.
Materials and methods: All NMIBC-patients from a well-characterized population based cohort were
analyzed (n¼88). Polymorphism data were combined with information from 15-years of clinical follow-
up. The effect of BCG-treatment on cancer-speciﬁc death (CSD), recurrence and progression in patients
with varying NOS-genotypes were studied using Cox proportional hazard-models and log rank tests.
Results: BCG-treatment resulted in signiﬁcantly better survival in patients without (Log rank: p¼0.006;
HR: 0.12, p¼0.048), but not in patients with a long version ((CCTTT)n ≧13 repeats) of the NOS2-promoter
microsatellite. The NOS3-rs2070744(TT) and rs1799983(GG)-genotypes showed decreased risk for CSD
(Log rank(TT): p¼0.001; Log rank(GG): p¼0.010, HR(GG): 0.16, p¼0.030) and progression (Log rank(TT):
po0.001, HR(TT): 0.05, p¼0.005; Log rank(GG): po0.001, HR(GG): 0.10, p¼0.003) after BCG-therapy
compared to the other genotypes. There was also a reduction in recurrence in BCG-treated patients that
was mostly genotype independent. Analysis of combined genotypes identiﬁed a subgroup of 30% of the
BCG-treated patients that did not beneﬁt from BCG-treatment.
Conclusions: Our results suggest that the investigated polymorphisms inﬂuence patient response to BCG-
treatment and thus may serve as possible markers for identiﬁcation of BCG-failures.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).B.V. This is an open access article u
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Urinary bladder cancer accounts for up to 5% of all new cancers
in the Western world, and commonly presents as a highly differ-
entiated tumor conﬁned to the bladder mucosa (Ta) or sub-mu-
cosa (T1) [1]. Despite advances in management of non-muscle
invasive bladder cancer (NMIBC), tumor recurrence and progres-
sion rates remain high.
Treatment with Bacillus Calmette-Guérin (BCG) is considered
the most effective intravesical treatment for NMIBC. NMIBC can be
divided into low, intermediate and high-risk bladder cancer with
respect to recurrence and disease progression [1]. In general, BCG
is not advocated for low-risk NMIBC due to its favorable prognosis.
In intermediate risk NMIBC, BCG is a well-established treatmentnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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controversial. In high-risk NMIBC, e.g. high grade (G3) and stage
T1 tumors, BCG has been shown to reduce disease progression [2],
and is still the most frequently used bladder-sparing option
available. Despite its efﬁcacy, a signiﬁcant proportion of BCG-
treated patients (30–35%) either relapse within the ﬁrst ﬁve years
after treatment or fail to respond at all [3]. High-risk NMIBC-pa-
tients failing to respond to BCG-treatment, and undergoing radical
cystectomy as second treatment , generally have a worse prognosis
than those undergoing immediate radical cystectomy [4]. Thus,
identiﬁcation of patients at risk for BCG failure is of high priority.
Although BCG is an established treatment for bladder cancer its
precise mechanisms of action are not fully understood. Several
studies indicate a role for nitric oxide (NO) in the cytotoxic effect
that BCG exerts on bladder cancer cells [5,6]. NO is a biological
messenger with the ability to induce both anti-microbial and anti-
tumoral effects depending on cellular context. It is synthesized
from the conversion of L-arginine to L-citrullin by a family of three
NO synthases (NOS1-3). Altered expression of NOS2 and NOS3 has
been described in several human cancer forms, among them
bladder cancer, implicating that they may take part in cancer
biology [7–12]. Previously, we found associations between the
NOS2 promoter microsatellite (CCTTT)n polymorphism, the NOS3
promoter polymorphism rs2070744 (-786T4C), the NOS3 poly-
morphism rs1799983 (Glu298Asp) and the development and
progression of bladder cancer [8,12].
To evaluate polymorphisms as biological markers for bladder
cancer progression and patient survival, we here investigate the
association between NOS2 and NOS3 polymorphism in high-risk
NMIBC patients with respect to patient outcome after BCG-
treatment.2. Materials and methods
2.1. Study population
The patients included in this prospective study were drawn
from a population-based bladder cancer cohort consisting of 78%
(563/721) of all newly diagnosed bladder-cancer patients in the
Stockholm county, Sweden during 1995–1996, as previously de-
scribed [13]. For these patients we now have 15 years clinical
follow up, deﬁned as the time between diagnosis and last clinical
evaluation or death. Parameters registered were date of diagnosed
tumor recurrences, progress in grade/stage, development of nodal
or distant metastases, type of therapy and cause of death. For
grading the WHO1999 malignancy-grading system [14] was used
and tumor stage was assessed according to a modiﬁed TNM sys-
tem suggested by Hall and Prout [15]. Venous blood (normal tis-
sue) was collected at a later time point and was available for 359
patients, who were genotyped for the NOS2 promoter micro-
satellite (CCTTT)n polymorphism, the NOS3 promoter poly-
morphism rs2070744 (-786T4C), and the NOS3 exon 7 poly-
morphism rs1799983 (Glu298Asp) [8,12]. For the present study, all
patients with high-risk NMIBC (i.e. either TaG3, T1,
TaG1þconcomitant carcinoma in situ (conCIS), TaG2þconCIS or
primary CIS transitional cell carcinoma), i.e. 25% of the patients
(88/359), were included. Genotyping data for the NOS2 and NOS3
polymorphisms were combined with clinical parameters on can-
cer-speciﬁc death (CSD), disease progression and recurrence. In-
formed written consent was obtained from all participants, and
the study was approved by the regional Ethical Committee.
2.2. Study design
The NOS2 (CCTTT)n microsatellite promoter (2.6 kb)polymorphism was analyzed by DNA fragment analysis as pre-
viously described [8]. The NOS3 polymorphisms rs2070744 and
rs1799983 were analyzed by Allelic discrimination on an ABI
Prisms 7900HT sequence detection system, also as previously
described [12]. The researcher performing the genotyping did not
have any pre-knowledge of what treatment the different patients
had received. Based on our previous observation that patients
homozygous for a long set of repeats of the (CCTTT)n micro-
satellite had a higher risk for stage progression and CSD [8], we
grouped the patients into carriers of a long allele (L-carrier,
(CCTTT)nZ13 repeats) or non-carriers (non-L-carrier), with the
hypothesis that carrying long repeats was a disadvantage. For the
NOS3 polymorphisms, recessive models were used for the statis-
tical analyses due to the low frequencies of individuals homo-
zygous for the minor NOS3-alleles. Thus, for the NOS3 rs2070744
polymorphism individuals homozygous for the minor C-allele
(n¼8/87; 5.7%) were analyzed together with the heterozygotes, as
a CT/CC-group. For the NOS3 rs1799983 polymorphism the pa-
tients homozygous for the minor T-allele (n¼4/64; 2.9%) were
analyzed together with the heterozygotes, as a GT/TT-group.
2.3. Statistical analysis
Age, sex and tumor stage and grade adjusted hazard ratios (HR)
were calculated with stepwise backward selection models (Cox
proportional hazards) to assess the risk of CSD (deﬁned as bladder
cancer as the cause of death according to medical records), disease
progression (deﬁned as tumor stage T2 or more advanced, the
presence of a metastasis (nodal or distant), or death caused by
bladder cancer) and recurrence (deﬁned as return of disease in any
form; In the group of BCG-treated patients, recurrence that oc-
curred before BCG treatment started has been excluded from the
study) in BCG responders and non-responders. All HRs are shown
with a 2-sided 95% Conﬁdence Interval (CI). Follow-up was deﬁned
as time from date of diagnosis to last clinical evaluation or death
from bladder cancer or other causes. Follow-up time for progres-
sion was deﬁned as time from date of diagnosis to ﬁrst progression
event, death or last clinical evaluation. Kaplan–Meier estimator
plot with the 2-sided log rank test is provided to visualize the
cumulative effect of polymorphisms over time. Associations be-
tween the polymorphisms were calculated with linkage dis-
equilibrium analyses and Pearson’s coefﬁcient of correlation. Sta-
tistical analyses were done with IBMs SPSSs Statistics, version
21.0.3. Results
The characterization of the study population is described in
Table 1. Overall, we found a signiﬁcant reduction in recurrence for
those patients who had received BCG. This reduction was in-
dependent of genotype, with the exception of the rs1799983
polymorphism, where the BCG-treated patients homozygous for
the G allele (GG) had a decreased risk for recurrence.
3.1. NOS2(CCTTT)n microsatellite promoter (2.6 kb) polymorphism
Genotyping of the (CCTTT)n microsatellite promoter poly-
morphism was successful in all 88 patients with high-risk NMIBC.
Of these, 51 patients had received BCG-treatment at some point. In
L-carrier patients (n¼45) there were no differences in CSD be-
tween those who had received BCG and those who had not (Ta-
ble 2). However, in non-L-carriers (n¼43) the risk of CSD was
signiﬁcantly reduced for those patients who had received BCG
(HR: 0.12; CI: 0.02–0.98; p¼0.048) (Table 2). There was also a
reduction in disease progression for those who had received BCG,
Table 1
Study population.
BCG treated Non-BCG treated Total
N.o.Pts (%)a conCISb N.o.Pts (%)a conCISb N.o.Pts (%)a conCISb
TaG3 9 (18) 4 4 (11) 0 13 (15) 4
T1G1/G2 11 (22) 0 18 (49) 0 29 (33) 0
T1G3 19 (37) 5 15 (41) 2 34 (39) 7
TaG1/G2þconCIS 3 (6) 3 0 (0) 0 3 (3) 3
Primary CIS 9 (18) N.A. 0 (0) N.A. 9 (10) N.A.
Total (N.o. Pts) 51 37 88
Mean age (years) 69.7 70.7 70.4
a Number (N.o. Pts) and percentage (%) of high-risk NMIBC-patients with different tumor stage and grade.
b Number of patients within each tumor stage and grade category having concomitant carcinoma in situ (conCIS).
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difference was found between the L-carrier and the non-L-carrier
groups (Table 2).
3.2. NOS3 promoter polymorphism rs2070744
Genotyping was successful in 87/88 (99%) of the high-risk
NMIBC patients of which 50 had received BCG-treatment. None of
the TT-patients, 0/21 (0.0%), treated with BCG died from bladder
cancer during the time of follow-up, while 7 out of the 18 (38.9%)
TT-patients who were not treated with BCG died from CSD during
the same period (Table 2). Also, TT-patients had a signiﬁcantly
decreased risk for disease progression after BCG-treatment (HR:
0.05; CI: 0.01–0.42; p¼0.005, Table 2). In patients with the CT and
CC genotypes, BCG gave no advantage regarding CSD and disease
progression compared to those who had not received BCG
(Table 2).
3.3. NOS3 exon polymorphism rs1799983
Genotyping was successful in 64/88 (76%) of the high-risk
NMIBC patients, of which 34 had received BCG-treatment. Patients
homozygous for the G allele (GG) and treated with BCG had a
signiﬁcantly decreased risk for CSD compared to those who had
not received BCG (HR: 0.16; CI: 0.03–0.84; p¼0.030, Table 2). Pa-
tients homozygous for the G allele (GG) that were treated with
BCG also had a decreased risk for recurrence (HR: 0.29; CI: 0.10–
00.87; p¼0.028) and for disease progression (HR: 0.10; CI: 0.02–
0.46; p¼0.003, Table 2). In patients with the GT and TT genotypes
BCG gave no advantage regarding CSD, recurrence or disease
progression in comparison to those who had not received BCG
(Table 2)
3.4. Combinatorial effects of NOS-genotypes
Linkage analyzes showed a moderate correlation between the
two NOS3-polymorphisms (r: 0.14; po0.001), but no correlations
between the two NOS3-polymorphisms and the NOS2 (CCTTT)n
microsatellite promoter polymorphism. When combining the
genotypes of the investigated polymorphisms in all high-risk
NMIBC-patients, those patients with one or more of either (1)
NOS2 (CCTTT)non-L-carrier (homozygous), (2) NOS3-rs2070744
(TT) or (3) rs1799983 (GG) genotypes, had a signiﬁcant advantage
from BCG-treatment regarding both CSD (HR: 0.17; CI: 0.05–0.59;
p¼0.006, Table 3) and disease progression (HR: 0.21; CI: 0.08–
0.55; p¼0.002, Table 3), while patients without these genotypes
had no signiﬁcant advantage of BCG-treatment.
Analyses of genotypes only within the group of BCG-treated
patients (n¼51) show that those (n¼36; 70.6%) with at least one
of either (1) NOS2 (CCTTT)non-L-carrier (homozygous), (2) NOS3-rs2070744 (TT) or (3) rs1799983 (GG) genotypes had a sig-
niﬁcantly better cancer speciﬁc survival (HR: 0.20; CI: 0.05–0.85;
p¼0.029; Log-rank test: p¼0.037), and a decreased risk of recur-
rence (HR: 0.54; CI: 0.23–1.27; p¼0.160; Log-rank test: p¼0.035),
than patients without these three genotypes (Fig. 1).4. Discussion
Our data show that the investigated NOS-polymorphisms are
associated with progression and CSD after BCG-treatment in pa-
tients with high-risk NMIBC. By combining the investigated gen-
otypes, we were also able to identify a subgroup of patients who
did not beneﬁt from the BCG treatment. Patients homozygous or
heterozygous for a long set of NOS2 (CCTTT)n repeats (L-carriers)
had a signiﬁcantly higher risk for CSD after BCG-treatment com-
pared to the non-L-carriers. The NOS3-polymorphisms inﬂuenced
the risk for both CSD and disease progression after BCG-treatment,
in favor for those with the rs2070744 (TT) and the rs1799983
(GG)-genotypes. The effect of BCG-treatment on bladder tumor
recurrence was signiﬁcant across all genotype groups, except for
the rs1799983 GT/TT-group where the effect was moderate.
However, after stratiﬁcation into treatment groups (BCG/not BCG),
a combined genotype effect was seen within the BCG-treated
group, with a decreased risk of recurrence in the group of patients
carrying at least one of either (1) NOS2 (CCTTT)non-L-carrier
(homozygous), (2) NOS3- rs2070744 (TT) or (3) rs1799983 (GG)
genotypes.
Several studies suggest an anti-tumor promoting effect of NO
after BCG treatment [7,16]. BCG was also one of the ﬁrst com-
pounds shown to induce NO-synthesis in activated macrophages,
which in turn promoted their cytotoxic effects against tumor cells
[17]. However, not all tumors respond with growth arrest and
apoptosis when exposed to NO. One theory, supported by several
studies, is that this effect is caused by an acquired resistance to NO,
following a prolonged exposure to low NO-concentrations, which
later offers a protection to higher levels [18]. In accordance, mainly
NOS2-expressing tumors, at the ﬁrst resection, have been shown to
recur after BCG-treatment [16,19]. It is plausible that polymorph-
isms in part regulate NOS-expression and functional in vitro stu-
dies of the (CCTTT)n repeat polymorphism have shown that in-
creased NOS2 gene expression correlate to an increased number of
(CCTTT)n repeats, due to a more active promoter [20,21]. It is
possible that patients with longer (CCTTT)n repeats after NOS2-
induction could produce higher NO concentrations for a longer
time, which by itself can be pro-metastatic in the established tu-
mor and also cause resistance to the high levels of NO seen after
BCG-treatment. In theory, this could be one explanation to why we
see a repressed response to BCG in L-carriers compared to non-L-
carriers.
Table 2
Cancer speciﬁc death, disease progression and recurrence in patients with high-risk
NMIBC.
N.o. Pts/total
N.o. (%)
Adjusted HR (95%
CI)
p-Value
NOS2 (CCTTT)n microsatellite promoter (2.6 kb)
CSD
L-carriers Not BCG
treated
5/14 (36) 1.0
BCG treated 7/31 (23) 0.61 (0.19–1.92) 0.349
Non-L-carriers Not BCG
treated
9/23 (39) 1.0
BCG treated 1/20 (5) 0.12 (0.02–0.98) 0.048
Progression
L-carriers Not BCG
treated
9/14 (64) 1.0
BCG treated 8/31 (26) 0.28 (0.11–0.73) 0.009
Non -L-carriers Not BCG
treated
12/23 (52) 1.0
BCG treated 3/20 (15) 0.22 (0.06–0.77) 0.018
Recurrence
L-carriers Not BCG
treated
11/14 (79) 1.0
BCG treated 16/31 (52) 0.31 (0.14–0.69) 0.004
Non-L-carriers Not BCG
treated
16/23 (70) 1.0
BCG treated 6/20 (30) 0.20 (0.08–0.54) 0.001
rs2070744 (NOS3 -786T4C)
CSD
TT Not BCG
treated
7/18 (39) 1.0
BCG treated 0/21 (0) – a
CT/CC Not BCG
treated
7/19 (37) 1.0
BCG treated 8/29 (28) 0.81 (0.28–2.32) 0.696
Progression
TT Not BCG
treated
11/18 (61)
BCG treated 1/21 (5) 0.05 (0.01–0.42) 0.005
CT/CC Not BCG
treated
10/19 (53) 1.0
BCG treated 10/29 (35) 0.53 (0.22–1.28) 0.156
Recurrence
TT Not BCG
treated
12/18 (67) 1.0
BCG treated 5/21 (24) 0.23 (0.08–0.70) 0.009
CT/CC Not BCG
treated
15/19 (79) 1.0
BCG treated 17/29 (59) 0.25 (0.11–0.54) o0.001
rs1799983 (NOS3 Glu298Asp)
CSD
GG Not BCG
treated
6/12 (50) 1.0
BCG treated 2/17 (12) 0.16 (0.03–0.84) 0.030
GT/TT Not BCG
treated
6/18 (33) 1.0
BCG treated 4/17 (24) 0.88 (0.24–3.22) 0.845
Progression
GG Not BCG
treated
9/12 (75) 1.0
BCG treated 3/17 (18) 0.10 (0.02–0.46) 0.003
GT/TT Not BCG
treated
9/18 (50) 1.0
BCG treated 5/17 (29) 0.67 (0.21–2.15) 0.505
Recurrence
GG Not BCG
treated
9/12 (75) 1.0
BCG treated 7/17 (41) 0.29 (0.10–00.87) 0.028
GT/TT Not BCG
treated
13/18 (72) 1.0
BCG treated 12/17 (71) 0.54 (0.24–1.20) 0.130
Data are presented as Hazard ratios (HR), adjusted for age, sex and tumor stage and
grade, in a stepwise selection model, for each of the NOS-polymorphisms.
Number of patients is abbreviated as N.o. Pts.
p-value less than 0.05, are shown in bold and italic.
a Since no BCG-treated TT-patients died it was not possible to calculate any
hazard ratios.
Table 3
Cancer speciﬁc death, disease progression and recurrence in patients with high-risk
NMIBC.
N.o. Pts/total
N.o. (%)
Adjusted HR (95%
CI)
p-Value
CSD
Basal level
NO
Not BCG
treated
13/33 (39) 1.0
BCG treated 3/36 (8) 0.17 (0.05–0.59) 0.006
High/low NO Not BCG
treated
1/4 (25) 1.0
BCG treated 5/15 (33) 3.04 (0.35–26.4) 0.314
Progression
Basal level
NO
Not BCG
treated
18/33 (55) 1.0
BCG treated 6/36 (17) 0.21 (0.08–0.55) 0.002
High/low NO Not BCG
treated
2/4 (50) 1.0
BCG treated 5/15 (33) 1.34 (0.26–7.01) 0.731
Recurrence
Basal level
NO
Not BCG
treated
23/33 (70) 1.0
BCG treated 12/36 (33) 0.28 (0.13–00.58) 0.001
High/low NO Not BCG
treated
4/4 (100) 1.0
BCG treated 10/15 (67) 0.10 (0.02–0.54) 0.008
Data are presented as Hazard ratios (HR), adjusted for age, sex and tumor stage and
grade, in a stepwise selection model. Basal level NO: patients with at least one of
the alleles NOS2(CCTTT)non-L-carrier, NOS3-786T4C(TT) or Glu298Asp(GG) were
considered to yield basal level levels of NO (i.e. neither increased, nor decreased
gene activity). High/low NO: patients with the NOS2(CCTTT)L-carrier, NOS3-
786T4C(CT/CC) and Glu298Asp(GT/TT) genotypes were considered to have altered
gene activity in both the NOS2 and the NOS3 genes.
Number of patients is abbreviated as N.o. Pts.
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shown to reduce the NOS3 promoter activity and it has been as-
sociated with decreased levels of serum nitrite/nitrate and en-
dothelial NO-production in humans [22]. Furthermore, over-
expressing NOS3 in the breast cancer cell line MCF-7 resulted in
elevated basal NO levels, which stimulated apoptosis and dimin-
ished cancer cell invasion [23]. This indicates that a decreased
NOS3 activity could increase the risk for developing cancer, which
is consistent with our earlier data where an association was found
between bladder cancer development and homozygous carriers of
the C-allele [12]. Also in the NOS3 rs1799983 polymorphism it has
been shown that carriers of the less common T-allele have a lower
level of nitrate/nitrite in urine and a lower NOS activity than car-
riers of the GG genotype [24].
Our study implicates that patients with the NOS3 polymorph-
ism genotypes rs2070744 (TT) and rs1799983 (GG) responded
better to BCG treatment than those with the NOS3 genotypes that
theoretically decrease NOS3 activity.
Combined analyses of all three NOS-polymorphisms showed
that patients with genotypes that neither increased NOS2 gene
activity, nor decreased NOS3 gene activity (i.e. patients with basal
level gene activity in both the NOS2 and NOS3 gene) had the best
response to BCG-treatment. For the subgroup of BCG-treated pa-
tients (15/51, approximately 30%) who were not homozygous for at
least one of the alleles associated with basal level gene activity
(NOS2 (CCTTT)non-L-carrier, NOS3-rs2070744 (TT) or rs1799983
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Fig. 1. Difference in survival after BCG-treatment. Comparison within the group of the BCG-treated patients (n¼51), between those with at least one of the NOS2(CCTTT)
non-L-carrier, NOS3-rs2070744(TT) or rs1799983(GG) considered to yield basal levels of NO (i.e. neither increased NOS2 gene activity, nor decreased NOS3 gene activity)
(n¼36/51; 70.6%; Basal level NO), and those with the NOS2(CCTTT)L-carrier, NOS3- rs2070744(CT/CC) and rs1799983(GT/TT) genotypes, who in theory have increased NOS2
gene activity and decreased activity in the NOS3 gene (n¼15/51; 29.4%; High/low NO). Patients still at risk are shown for each time point in the diagrams. (A) BCG-treated
patients with basal level of NOS-gene activity showed a signiﬁcantly better cancer speciﬁc survival (Log-rank test: p¼0.037), than BCG-treated patients with increased NOS2
and decreased NOS3-gene activity. (B) The difference in risk of disease progression between the two groups of BCG-treated patients with and without basal level of NOS-gene
activity was non-signiﬁcant (Log-rank test: p¼0.196). (C) BCG-treated patients with basal level of NOS-gene activity had a signiﬁcantly lower risk of recurrence (Log-rank
test: p¼0.035), than BCG-treated patients with increased NOS2 and decreased NOS3-gene activity.
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Many studies have previously discussed possible genetic bio-
markers for BCG-failures [25–27] to help distinguish patients who
would require a more aggressive initial treatment than BCG. Re-
cently, Kang et al. investigated GSTM1 and GSTT1 polymorphisms
and found an association with early BCG-failure [27]. However, so
far no exclusively convincing markers have been identiﬁed. Com-
bining the different ﬁndings of genetic polymorphisms suggested
to inﬂuence the outcome after BCG-treatment would be interest-
ing. Our ﬁndings, together with those of others, may help de-
termine whether patients would beneﬁt from BCG-treatment, or if
more aggressive treatment may be required.
This is a population-based study with a long follow-up, in-
cluding all patients with high-risk NMIBC where normal tissue
was available for genotyping, yet the study population is of limited
size. Since the study is of prospective design, there has been no
randomization to treatment, and regional traditions and physi-
cians’ choices decided whether the patient received BCG or not.
However, the numbers of patients in the BCG-treated versus the
non-BCG treated group were approximately the same. We did not
measure the concentration and activity of the NOS-enzymes di-
rectly in the patients, but instead relied on the association be-
tween these polymorphisms and altered enzyme activity pre-
viously shown in many studies [20–23,28]. A limitation of this
study is that interethnic differences in polymorphic frequencies
may limit the applicability of our ﬁndings to populations of Cau-
casian origin [29].5. Conclusion
Radical surgery in BCG-non-responders often results in a less
favorable prognosis than in those patients undergoing immediateradical cystectomy. Using polymorphisms as prognostic markers
may be a possible way to select those high-risk NMIBC-patients
who will be at risk of BCG-failure, and thus allow earlier initiation
of alternative treatments in this set of patients. Using the NOS2
(CCTTT)non-L–carrier (homozygous), NOS3-rs2070744 (TT) and
rs1799983 (GG) genotypes as inclusion criteria for selecting pa-
tients for BCG-treatment, only 71% of the BCG-treated patients in
the present cohort would have been selected. Within the subgroup
of BCG non-responders, immediate radical cystectomy instead of
BCG as primary treatment could probably have increased the
survival rate, had we known how to identify these patients at an
earlier stage. Although our results need to be conﬁrmed in larger
studies that validate the effects of NOS-polymorphisms on the
outcome after BCG-treatment, our study indicates that the NOS2
(CCTTT)n promoter polymorphism and the two NOS3 poly-
morphisms, rs2070744 and rs1799983, may predict the outcome
of BCG-treatment in high-risk NMIBC-patients, and as such may
serve as possible molecular markers to identify patients suitable
for BCG-treatment.Acknowledgement
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